Tanya Siddiqi, MD, discussed the CAR T-cell trial ahead of the ASH Annual Meeting & Exposition in an interview with CancerNetwork®.
In an interview with Cancer Network, Brad S. Kahl, MD, weighs in on the top CLL research presented at ASH 2018 in San Diego.
Researchers analyzed a new recurrent BCL2 mutation appearing in a cohort of patients with CLL-type progressions treated with venetoclax.
Leukemia cells show sensitivity to restriction of BCL2 and BTK with the combination of venetoclax and ibrutinib.
Researchers used high throughput drug screening on leukemic stem cells to determine drug resistance and sensitivity in acute myeloid leukemia patients.
Allogeneic hematopoietic stem cell transplantation could improve outcomes of elderly patients with acute myeloid leukemia.
Acalabrutinib continues to yield high response rates in patients with relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma.
The novel agent ivosidenib is well tolerated and induces durable responses in patients with relapsed/refractory acute myeloid leukemia and other hematologic malignancies.
Next-generation sequencing could be a powerful and independent predictor for relapse and survival among adults with acute myeloid leukemia.
A combination of ibrutinib plus standard chemoimmunotherapy induces deep responses in a relatively high-risk group of previously untreated, young chronic lymphocytic leukemia patients, according to a new study.